We recently published a list of 15 Stocks ChatGPT Predicts Could Make You Wealthy in 10 Years. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks ChatGPT predicts could make you wealthy in 10 years.

Medical-technology and drug company's 2025 sales outlook is below consensus Johnson & Johnson's stock ... from Dow Jones Newswires and The Wall Street Journal. We sell different types of products ...

Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Lee

Project Stargate will see companies like Oracle, SoftBank, MGX, and OpenAI commit an initial $100 billion to build data centers in the U.S.

Analysts on Wall Street project that Johnson & Johnson (JNJ) will announce quarterly earnings of $2 per share in its forthcoming report, representing a decline of 12.7% year over year. Revenues ...

JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price target - 13% upside

What Hartford Funds and Ned Davis Research found was that income stocks more than doubled the average annual return of non-payers -- 9.17% versus 4.27% -- and did so while being less volatile than the benchmark S&P 500. However, high-quality dividend stocks don't grow on trees and require some effort by investors to uncover.

Pharma giant Johnson & Johnson is buying Intra-Cellular Therapies, eying sales growth above analysts’ expectations through 2029.

House Speaker Mike Johnson revealed President Biden insisted to him he hadn’t issued an executive order freezing liquid natural gas export permits — despite doing so less than a month

Wall Street indexes hit new highs, driven by optimism in tech stocks, following President Trump's announcement of a $500 billion AI infrastructure plan. Netflix soared on strong subscriber numbers, while semiconductor shares surged on AI excitement.

Five magnificent income stocks -- sporting an average yield of 4.26% -- can pad investors' pocketbooks in the new year (and well beyond).